RECRUITING

Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to measure synaptic density in the brain comparing individuals with cocaine use disorder to healthy controls.

Official Title

Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study

Quick Facts

Study Start:2021-07-20

Study Completion:2026-06

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04721418

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 60 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* Age 21-60 years * Physically healthy by medical history, physical, neurological, ECG and laboratory examinations * For females, a negative serum pregnancy test * For CUD: DSM-5 criteria for Cocaine Use Disorder and positive urine toxicology showing recent use * For HC: Negative urine toxicology	* DSM-5 criteria for other substance use disorders (e.g., alcohol, opiates, sedative hypnotics), except for nicotine * A primary DSM-5 Axis I major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) as determined by the Structured Clinical Interview for DSM-5 (SCID-5) * A history of significant and/or uncontrolled medical or neurological illness * Current use of psychotropic and/or potentially psychoactive prescription medications * Medical contraindications to MRI procedure

Inclusion Criteria

Exclusion Criteria

* Age 21-60 years
* Physically healthy by medical history, physical, neurological, ECG and laboratory examinations
* For females, a negative serum pregnancy test
* For CUD: DSM-5 criteria for Cocaine Use Disorder and positive urine toxicology showing recent use
* For HC: Negative urine toxicology

* DSM-5 criteria for other substance use disorders (e.g., alcohol, opiates, sedative hypnotics), except for nicotine
* A primary DSM-5 Axis I major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) as determined by the Structured Clinical Interview for DSM-5 (SCID-5)
* A history of significant and/or uncontrolled medical or neurological illness
* Current use of psychotropic and/or potentially psychoactive prescription medications
* Medical contraindications to MRI procedure

Contacts and Locations

Study Contact

Marcella Mignosa, MD

CONTACT

203 974 7557

marcella.mignosa@yale.edu

Principal Investigator

Gustavo Angarita, MD

PRINCIPAL_INVESTIGATOR

Yale University

Study Locations (Sites)

Connecticut Mental Health Center

New Haven, Connecticut, 06519

United States

Collaborators and Investigators

Sponsor: Yale University

Gustavo Angarita, MD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-07-20

Study Completion Date2026-06

Study Record Updates

Study Start Date2021-07-20

Study Completion Date2026-06

Terms related to this study

Additional Relevant MeSH Terms

Cocaine Use Disorder
Healthy Controls